January 22, 2024
Rumors of China’s Decline Are Premature and Dangerous
Speaking in Davos, Switzerland, last week, Chinese Premier Li Qiang pitched his country as a solid investment destination. The Chinese economy, Li said, has “huge potential,” and choosing it “is not a risk, but an opportunity.”
His audience listened skeptically. After decades of unstoppable Chinese economic, demographic and military growth, the past two years have seen more trouble than triumphs. That has led some analysts to worry not about the rise of Chinese power but instead the irrevocable decline of China’s economy.
China continues to rise and seems bent on regional domination and international revisionism.
These fears are utterly premature. Worse, if they represent the assumptions on which U.S. policy is based, America will fail to rise to China’s challenge. The chief near-term risk is not that Beijing’s ascent will fizzle, but rather that Washington will fail to muster the strength necessary for an adequate response.
Read the full article from The Washington Post.
More from CNAS
-
Podcast
Defense / Indo-Pacific Security
Hellscape Taiwan: Drones, Deterrence, and the Future of Asymmetric DefenseStacie Pettyjohn joined the Irregular Warfare Podcast to examine how Taiwan could deter—or potentially defeat—a Chinese invasion by transforming the Taiwan Strait into an “unm...
By Stacie Pettyjohn
-
Video
Indo-Pacific Security / Energy, Economics & Security
Analysts Break Down Trump-Xi Meeting and Calls for Stability and CooperationFor perspective on President Trump's trip and the broader U.S.-China relationship, Geoff Bennett spoke with Myron Brilliant and Liza Tobin. Brilliant is at the DGA Group and i...
By Liza Tobin
-
Video
Indo-Pacific Security / Energy, Economics & Security
Rajdeep Sardesai Asks Big Question on US-ChinaThe debate on the Big Question, with Daniel Silverberg, adjunct senior fellow at the Center for a New American Security, explores whether Beijing holds the key to resolving th...
By Daniel Silverberg
-
China’s Pharmaceutical Weapon
Commentary
Until SAPIR is extended to biologically derived drugs, until the FDA clears the bovine pathway, and until at least one American-owned heparin manufacturer operates on US soil,...
By Jennifer Hendrixson White
